论文部分内容阅读
目的探讨序贯使用双歧三联活菌在根治幽门螺杆菌治疗中的作用。方法选取2012年10月-2014年10月收治的183例幽门螺杆菌阳性的慢性胃炎伴胃黏膜萎缩或糜烂患者,随机分为三联组、四联组、双歧三联活菌组,每组各61例。三联组给予标准三联1周疗法,四联组给予标准四联2周疗法,双歧三联活菌组给予标准四联疗法1周,序贯使用双歧三联活菌1周。停药1个月后比较3组患者幽门螺杆菌根除率、临床疗效及不良反应发生情况。结果三联组幽门螺杆菌根除率为72.13%,显著低于四联组(93.44%)及双歧三联活菌组(90.16%),差异有统计学意义(P<0.05)。双歧三联活菌组幽门螺杆菌根除率略低于四联组,但差异无统计学意义(P>0.05)。四联组与双歧三联活菌组临床治疗总有效率分别为95.08%、91.80%,差异无统计学意义(P>0.05),均高于三联组,差异有统计学意义(P<0.05)。抗幽门螺杆菌治疗过程中发生不良反应11例,但均较轻微,采取对症治疗后好转。四联组不良反应发生率显著高于双歧三联活菌组,差异有统计学意义(P<0.05)。结论序贯使用双歧三联活菌胶囊可提高幽门螺杆菌根除率,有效缓解临床症状,减少不良反应,降低医疗费用。
Objective To investigate the role of sequential use of bifidobacterium triple viable bacteria in the treatment of Helicobacter pylori. Methods A total of 183 patients with Helicobacter pylori-positive chronic gastritis and gastric mucosal atrophy or erosion treated in our hospital from October 2012 to October 2014 were randomly divided into triple group, quadruple group and bifid triple viable group 61 cases. The triple therapy group received standard triple therapy for one week, quadruple therapy group received standard quadruple therapy, bifid triple therapy group received standard quadruple therapy for one week, sequential use of bifid triple active bacteria for one week. One month after discontinuation, the eradication rate, clinical efficacy and adverse reactions of Helicobacter pylori in the three groups were compared. Results The eradication rate of Helicobacter pylori in the triad group was 72.13%, which was significantly lower than that in the quadruple cohort (93.44%) and the bifidobacterium triple viable cohort (90.16%). The difference was statistically significant (P <0.05). The eradication rate of Helicobacter pylori in the live bifidobacterium group was slightly lower than that in the quadruple cohort group, but the difference was not statistically significant (P> 0.05). The total effective rate of clinical treatment in quadruple group and bifid triple viable group was 95.08% and 91.80%, respectively, with no significant difference (P> 0.05), which were significantly higher than triple group (P <0.05) . Anti-Helicobacter pylori in the course of treatment of adverse reactions in 11 cases, but were minor, to improve after symptomatic treatment. The incidence of adverse reactions in quadruple combined group was significantly higher than that in live bifidobacterium group (P <0.05). Conclusion Sequential use of bifid triple viable bacteria can improve H. pylori eradication rate, effectively relieve clinical symptoms, reduce adverse reactions, reduce medical costs.